Neonatal immune response and serum bactericidal activity induced by a meningococcal conjugate vaccine is enhanced by LT-K63 and CpG2006

Vaccine

Volumn 26, Issue 35, 2008, Pages 4557-4562

  Brynjolfsson, Siggeir F ^a,b   Bjarnarson, Stefania P ^a,b   Mori, Elena ^c   Del Giudice, Giuseppe ^c   Jonsdottir, Ingileif ^a,b,d  

^a LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^b UNIVERSITY OF ICELAND   (Iceland)

^c NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^d DECODE GENETICS   (Iceland)

Author keywords

Adjuvant; Antibody; Conjugate; Immunity; Memory; Meningococcus; Mucosal; Neonate; Serum bactericidal activity; Vaccine

Indexed keywords

ADJUVANT; BOVINE SERUM ALBUMIN; CPG2006; IMMUNOGLOBULIN G ANTIBODY; LT K63; MENINGOCOCCAL SEROGROUP C POLYSACCHARIDE CONJUGATE VACCINE; MENINGOCOCCUS VACCINE; POLYSACCHARIDE VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; BACTERICIDAL ACTIVITY; BLOOD GROUP TYPING; CONJUGATION; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; IMMUNE RESPONSE; IMMUNITY; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; IMMUNOMODULATION; MALE; MOUSE; NEISSERIA MENINGITIDIS; NEWBORN; NONHUMAN; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODY AFFINITY; BACTERIAL TOXINS; BLOOD BACTERICIDAL ACTIVITY; ENTEROTOXINS; ESCHERICHIA COLI PROTEINS; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN G; INJECTIONS, SUBCUTANEOUS; MENINGOCOCCAL VACCINES; MICE; MICROBIAL VIABILITY; OLIGODEOXYRIBONUCLEOTIDES;

EID: 48449101169     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.05.083     Document Type: Article

References (54)

1. Siegrist C.A. Neonatal and early life vaccinology. Vaccine 19 25-26 (2001) 3331-3346
2. Kvalsvig A.J., and Unsworth D.J. The immunopathogenesis of meningococcal disease. J Clin Pathol 56 6 (2003) 417-422
3. World Health Organization. Epidemics of meningococcal disease, African meningitis belt. Weekly Epidemiologic Rec 6 (2001) 281-288
4. Pollard A.J. Global epidemiology of meningococcal disease and vaccine efficacy. Pediatr Infect Dis J 23 12 Suppl (2004) S274-S279
5. Peltola H., Kayhty H., Sivonen A., and Makela H. Haemophilus influenzae type b capsular polysaccharide vaccine in children: a double-blind field study of 100,000 vaccinees 3 months to 5 years of age in Finland. Pediatrics 60 5 (1977) 730-737
6. Steinhoff M.C., Edwards K., Keyserling H., Thoms M.L., and Madore D. Immunologic priming of young children by pneumococcal glycoprotein conjugate, but not polysaccharide, vaccines. Pediatr Infect Dis J 15 5 (1996) 425-430
7. Robbins J.B., Schneerson R., Anderson P., and Smith D.H. Prevention of systemic infections, especially meningitis, caused by Haemophilus influenzae type b. JAMA 276 14 (1996) 1181-1185
8. Robbins J.B., Schneerson R., and Szu S.C. Hypothesis: how licensed vaccines confer protective immunity. Adv Exp Med Biol 397 (1996) 169-182
9. Jakobsen H., Bjarnarson S.P., Del Giudice G., Moreau M., Siegrist C.A., and Jonsdottir I. Intranasal immunization with pneumococcal conjugate vaccines with LT-K63, a non toxic mutant of heat-labile enterotoxin, as adjuvant rapidly induces protective immunity against lethal pneumococcal infections in neonatal mice. Infect Immun 70 3 (2002) 1443-1452
10. Bjarnarson S.P., Jakobsen H., Del Giudice G., Trannoy E., Siegrist C.A., and Jonsdottir I. The advantage of mucosal immunization for polysaccharide-specific memory responses in early life. Eur J Immunol 35 4 (2005) 1037-1045
11. Olafsdottir T.A., Hannesdottir S.G., Giudice G.D., Trannoy E., and Jonsdottir I. Effects of LT-K63 and CpG2006 on phenotype and function of murine neonatal lymphoid cells. Scand J Immunol 66 4 (2007) 426-434
12. Takahashi I., Marinaro M., Kiyono H., Jackson R.J., Nakagawa I., Fujihashi K., et al. Mechanisms for mucosal immunogenicity and adjuvanticity of Escherichia coli labile enterotoxin. J Infect Dis 173 (1996) 627-635
13. Douce G., Giuliani M.M., Gianelli V., Pizza M., Rappuoli R., and Dougan G. Mucosal immunogenicity of genetically detoxified derivatives of heat labile toxin from Escherichia coli. Vaccine 16 11-12 (1998) 1065-1073
14. Ryan E.J., McNeela E., Pizza M., Rappuoli R., ÓNeill L., and Mills K.H. Modulation of innate and acquired immune responses by Escherichia coli heat-labile toxin: distinct pro- and anti-inflammatory effects of the nontoxic AB complex and the enzyme activity. J Immunol 165 (2000) 5750-5759
15. Pizza M., Giuliani M.M., Fontana M.R., Monaci E., Douce G., Dougan G., et al. Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants. Vaccine 19 17-19 (2001) 2534-2541
16. Jakobsen H., Adarna B.C., Schulz D., Rappuoli R., and Jonsdottir I. Characterization of the antibody response to pneumococcal glycoconjugates and the effect of heat-labile enterotoxin on IgG subclasses after intranasal immunization. J Infect Dis 183 10 (2001) 1494-1500
17. Peppoloni S., Ruggiero P., Contorni M., Morandi M., Pizza M., Rappuoli R., et al. Mutants of the Escherichia coli heat-labile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines. Expert Rev Vaccines 2 2 (2003) 285-293
18. Krieg A.M., Yi A.K., Matson S., Waldschmidt T.J., Bishop G.A., Teasdale R., et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374 6522 (1995) 546-549
19. Hemmi H., Takeuchi O., Kawai T., Kaisho T., Sato S., Sanjo H., et al. A Toll-like receptor recognizes bacterial DNA. Nature 408 6813 (2000) 740-745
20. Klinman D.M., Yi A.K., Beaucage S.L., Conover J., and Krieg A.M. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci USA 93 7 (1996) 2879-2883
21. Davis H.L., Weeratna R., Waldschmidt T.J., Tygrett L., Schorr J., and Krieg A.M. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J Immunol 160 2 (1998) 870-876
22. Jakobsen H., Schulz D., Pizza M., Rappuoli R., and Jonsdottir I. Intranasal immunization with pneumococcal polysaccharide conjugate vaccines with nontoxic mutants of Escherichia coli heat-labile enterotoxins as adjuvants protects mice against invasive pneumococcal infections. Infect Immun 67 11 (1999) 5892-5897
23. Jakobsen H., and Jonsdottir I. Mucosal vaccination against encapsulated respiratory bacteria-new potentials for conjugate vaccines?. Scand J Immunol 58 2 (2003) 119-128
24. Lambert P.H., Liu M., and Siegrist C.A. Can successful vaccines teach us how to induce efficient protective immune responses?. Nat Med 11 4 Suppl (2005) S54-S62
25. Richter M.Y., Jakobsen H., Haeuw J.F., Power U.F., and Jonsdottir I. Protective levels of polysaccharide-specific maternal antibodies may enhance the immune response elicited by pneumococcal conjugates in neonatal and infant mice. Infect Immun 73 2 (2005) 956-964
26. Del Giudice G. Vaccination strategies. An overview. Vaccine 21 Suppl 2 (2003) S83-S88
27. Pizza M., Domenighini M., Hol W., Giannelli V., Fontana M.R., Giuliani M.M., et al. Probing the structure-activity relationship of Escherichia coli LT-A by site-directed mutagenesis. Mol Microbiol 14 1 (1994) 51-60
28. Kovarik J., Bozzotti P., Love-Homan L., Pihlgren M., Davis H.L., Lambert P.H., et al. CpG oligonucleotides can circumvent the Th2 polarization of neonatal responses to vaccines but may fail to fully redirect Th2 responses established by neonatal priming. J Immunol 162 (1999) 1611-1617
29. Gheesling L.L., Carlone G.M., Pais L.B., Holder P.F., Maslanka S.E., Plikaytis B.D., et al. Multicenter comparison of Neisseria meningitidis serogroup C anti-capsular polysaccharide antibody levels measured by a standardized enzyme-linked immunosorbent assay. J Clin Microbiol 32 6 (1994) 1475-1482
30. Goldblatt D., van Etten L., van Milligen F.J., Aalberse R.C., and Turner M.W. The role of pH in modified ELISA procedures used for the estimation of functional antibody affinity. J Immunol Methods 166 2 (1993) 281-285
31. Baudner B.C., Balland O., Giuliani M.M., Von Hoegen P., Rappuoli R., Betbeder D., et al. Enhancement of protective efficacy following intranasal immunization with vaccine plus a nontoxic LTK63 mutant delivered with nanoparticles. Infect Immun 70 9 (2002) 4785-4790
32. Maslanka S.E., Gheesling L.L., Libutti D.E., Donaldson K.B., Harakeh H.S., Dykes J.K., et al. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group. Clin Diagn Lab Immunol 4 2 (1997) 156-167
33. Andrews N., Borrow R., and Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin Diagn Lab Immunol 10 5 (2003) 780-786
34. Welsch J.A., Moe G.R., Rossi R., Adu-Bobie J., Rappuoli R., and Granoff D.M. Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity. J Infect Dis 188 11 (2003) 1730-1740
35. Costantino P., Viti S., Podda A., Velmonte M.A., Nencioni L., and Rappuoli R. Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and C. Vaccine 10 10 (1992) 691-698
36. Richmond P., Borrow R., Goldblatt D., Findlow J., Martin S., Morris R., et al. Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers. J Infect Dis 183 1 (2001) 160-163
37. MacDonald N.E., Halperin S.A., Law B.J., Forrest B., Danzig L.E., and Granoff D.M. Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial. JAMA 280 19 (1998) 1685-1689
38. MacLennan J.M., Shackley F., Heath P.T., Deeks J.J., Flamank C., Herbert M., et al. Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants: a randomized controlled trial. JAMA 283 21 (2000) 2795-2801
39. Ramsay M.E., Andrews N., Kaczmarski E.B., and Miller E. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet 357 9251 (2001) 195-196
40. Snape M.D., Perrett K.P., Ford K.J., John T.M., Pace D., Yu L.M., et al. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. JAMA 299 2 (2008) 173-184
41. Miller E., Salisbury D., and Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 20 Suppl 1 (2001) S58-S67
42. Trotter C.L., Edmunds W.J., Ramsay M.E., and Miller E. Modeling future changes to the meningococcal serogroup C conjugate (MCC) vaccine program in England and Wales. Hum Vaccin 2 2 (2006) 68-73
43. Ramsay M.E., Andrews N.J., Trotter C.L., Kaczmarski E.B., and Miller E. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ 326 7385 (2003) 365-366
44. Baudner B.C., Giuliani M.M., Verhoef J.C., Rappuoli R., Junginger H.E., and Giudice G.D. The concomitant use of the LTK63 mucosal adjuvant and of chitosan-based delivery system enhances the immunogenicity and efficacy of intranasally administered vaccines. Vaccine 21 25-26 (2003) 3837-3844
45. Baudner BC. Mucosal vaccine delivery. The concominant use of chitosan-based delivery systems and adjuvants for improved efficacy of nasally administered Neisseria meningitis vaccines. PhD thesis, Leiden University; 2005.
46. Adarna BC. Immune responses to novel pneumococcal conjugates and effects of novel adjuvants. MSc thesis, University of Iceland; 2004.
47. Clark M.R. IgG effector mechanisms. Chem Immunol 65 (1997) 88-110
48. Borrow R., Balmer P., and Miller E. Meningococcal surrogates of protection-serum bactericidal antibody activity. Vaccine 23 17-18 (2005) 2222-2227
49. Lucas A.H., and Granoff D.M. Functional differences in idiotypically defined IgG1 anti-polysaccharide antibodies elicited by vaccination with Haemophilus influenzae type B polysaccharide-protein conjugates. J Immunol 154 8 (1995) 4195-4202
50. Schlesinger Y., and Granoff D.M. Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines. The Vaccine Study Group. JAMA 267 11 (1992) 1489-1494
51. Usinger W.R., and Lucas A.H. Avidity as a determinant of the protective efficacy of human antibodies to pneumococcal capsular polysaccharides. Infect Immun 67 5 (1999) 2366-2370
52. McHeyzer-Williams M.G., and Ahmed R. B cell memory and the long-lived plasma cell. Curr Opin Immunol 11 2 (1999) 172-179
53. Borrow R., Richmond P., Kaczmarski E.B., Iverson A., Martin S.L., Findlow J., et al. Meningococcal serogroup C-specific IgG antibody responses and serum bactericidal titres in children following vaccination with a meningococcal A/C polysaccharide vaccine. FEMS Immunol Med Microbiol 28 1 (2000) 79-85
54. Richmond P., Goldblatt D., Fusco P.C., Fusco J.D., Heron I., Clark S., et al. Safety and immunogenicity of a new Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in healthy adults. Vaccine 18 7-8 (1999) 641-646